SKYE · Skye Bioscience, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $7.94M | - | $9.36M | $14.34M | $7.20M | - | $4.88M | $1.79M | $1.95M | - |
| SG&A | $4.74M | - | $3.91M | $3.91M | $4.56M | - | $4.64M | $4.33M | $4.21M | - |
| Total Operating Expenses | $12.67M | - | $13.26M | $18.24M | $11.76M | - | $4.97M | $8.41M | $6.15M | - |
| D&A | $172.9K | - | - | - | $27.6K | - | $12.8K | - | $27.6K | - |
| Operating Income | ($12.67M) | - | ($13.26M) | ($18.24M) | ($11.76M) | - | ($4.97M) | ($8.41M) | ($6.15M) | - |
| Interest Expense | $2.2K | - | $0 | $0 | $436.9K | - | ($90.8K) | $450.1K | $436.9K | - |
| Income Tax | $0 | - | $0 | $3.4K | $2.0K | - | $0 | $8.1K | $2.0K | - |
| Net Income | ($12.51M) | - | ($12.75M) | ($17.62M) | ($11.10M) | - | ($3.90M) | ($7.90M) | ($5.02M) | - |
| EPS - Basic | ($0.32) | - | ($0.32) | ($0.44) | ($0.28) | - | ($0.10) | ($0.20) | ($0.18) | - |
| EPS - Diluted | ($0.32) | - | ($0.32) | ($0.44) | ($0.28) | - | ($0.10) | ($0.20) | ($0.18) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.15M | $5.88M | $18.44M | $23.84M | $46.42M | $68.42M | $67.41M | $74.12M | $83.34M | $10.34M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.94M | $2.03M | $2.83M | $3.22M | $569.3K | - | $780.0K | $1.08M | $1.16M | - |
| Current Assets | $18.57M | $27.09M | $39.92M | $50.58M | $63.03M | $70.83M | $79.81M | $87.00M | $94.57M | $11.65M |
| Total Assets | $19.42M | $28.31M | $41.32M | $52.16M | $64.79M | $72.76M | $81.54M | $87.26M | $94.84M | $11.94M |
| Current Liabilities | $10.40M | $8.21M | $8.37M | $8.31M | $5.32M | $4.34M | $5.62M | $14.32M | $15.80M | $13.90M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $10.40M | $8.29M | $8.49M | $8.48M | $5.54M | $4.61M | $5.73M | $14.45M | $15.95M | $14.07M |
| Stockholders' Equity | $9.01M | $20.02M | $32.84M | $43.68M | $59.25M | $68.15M | $75.80M | $72.81M | $78.88M | ($2.13M) |
| Retained Earnings | ($199.38M) | ($186.87M) | ($172.43M) | ($159.68M) | ($142.05M) | ($130.95M) | ($121.20M) | ($117.30M) | ($109.40M) | ($104.38M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($8.56M) | - | - | - | ($9.19M) | - | - | - | ($4.71M) | - |
| Investing Cash Flow | $10.90M | - | - | - | ($12.81M) | - | - | - | $1.14M | - |
| Financing Cash Flow | ($71.5K) | - | - | - | $0 | - | - | - | $85.65M | - |
| CapEx | $0 | - | - | - | $6.3K | - | - | - | $3.2K | - |
| Free Cash Flow | ($8.56M) | - | - | - | ($9.19M) | - | - | - | ($4.71M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.68 | - | - | - | 0.83 | - | - | - | 0.94 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -64.4% | - | -30.9% | -33.8% | -17.1% | - | -4.8% | -9.1% | -5.3% | - |
| Return on equity | -138.8% | - | -38.8% | -40.4% | -18.7% | - | -5.1% | -10.9% | -6.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.78 | 3.30 | 4.77 | 6.09 | 11.85 | 16.32 | 14.19 | 6.07 | 5.99 | 0.84 |
| Quick ratio | 1.78 | 3.30 | 4.77 | 6.09 | 11.85 | 16.32 | 14.19 | 6.07 | 5.99 | 0.84 |
| Cash ratio | 0.78 | 0.72 | 2.20 | 2.87 | 8.73 | 15.77 | 11.99 | 5.18 | 5.27 | 0.74 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -5763.7x | - | - | - | -26.9x | - | 54.7x | -18.7x | -14.1x | - |
| Equity multiplier | 2.15 | 1.41 | 1.26 | 1.19 | 1.09 | 1.07 | 1.08 | 1.20 | 1.20 | -5.60 |
| Liabilities / Assets | 0.54 | 0.29 | 0.21 | 0.16 | 0.09 | 0.06 | 0.07 | 0.17 | 0.17 | 1.18 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 2.7x | - | 4.7x | 3.8x | 1.1x | - | 2.0x | 4.3x | 5.6x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -7.8% | - | -167.0% | -117.0% | -91.1% | - | 79.9% | -195.7% | -98.4% | - |
| Net income growth (YoY) | -12.7% | - | -227.2% | -123.0% | -121.2% | - | 84.4% | -154.0% | 2.9% | - |
| EPS growth (YoY) | -14.3% | - | -220.0% | -120.0% | -55.6% | - | 96.8% | - | -1700.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 6.9% | - | - | - | -95.1% | - | - | - | -16.0% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -84.8% | -70.6% | -56.7% | -40.0% | -24.9% | - | 4371.5% | - | - | 29.1% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Skye Bioscience against the 5 most active filers in the same SIC group.